5,000 Shares of Moderna, Inc. $MRNA Bought by Credit Capital Investments LLC

Key Points

• Credit Capital Investments LLC bought 5,000 Moderna shares worth approximately $963,000 during the third quarter, making Moderna 0.4% of its portfolio. Institutional investors collectively own 75.33% of the company.
• Moderna and Merck reported Phase 3 results showing their personalized mRNA melanoma vaccine reduced the risk of recurrence or death by 42% when used with Keytruda, strengthening the company’s oncology pipeline and potential revenue diversification beyond COVID-19 vaccines.
• Despite the positive data, Moderna shares faced volatility after trial results leaked and fell short of elevated market expectations. Analysts maintain a consensus “Hold” rating with an average price target of $103.95, while recent insider sales were conducted under pre-arranged Rule 10b5-1 plans.

Credit Capital Investments LLC acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 5,000 shares of the company's stock, valued at approximately $963,000. Moderna makes up 0.4% of Credit Capital Investments LLC's holdings, making the stock its 19th biggest holding.

Other hedge funds also recently added to or reduced their stakes in the company. Western Pacific Wealth Management LP purchased a new stake in Moderna during the 3rd quarter worth approximately $29,000. Allied Private Wealth LLC acquired a new stake in Moderna during the 2nd quarter worth approximately $30,000. Canton Hathaway LLC purchased a new position in Moderna in the 1st quarter valued at approximately $31,000. Archer Investment Corp purchased a new position in Moderna in the 2nd quarter valued at approximately $36,000. Finally, Assetmark Inc. boosted its position in Moderna by 35.1% in the 1st quarter. Assetmark Inc. now owns 801 shares of the company's stock valued at $41,000 after buying an additional 208 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna and Merck reported positive Phase 3 INTerpath-001 results for the personalized mRNA cancer vaccine, intismeran autogene, used with Keytruda. The treatment reduced the risk of melanoma recurrence or death by 42%, while also improving distant metastasis-free survival. Oncologists described the findings as a major advance in melanoma care. Nature article
• Positive Sentiment: The results strengthen the case for Moderna’s oncology pipeline and could support a major future revenue stream beyond COVID-19 vaccines, particularly if additional trials demonstrate benefits in other cancers. Moderna has also advanced its mRNA bird-flu vaccine into a late-stage trial, adding another potential pipeline catalyst. Bird flu vaccine trial article
• Neutral Sentiment: Moderna’s recent addition to the Nasdaq-100 and analyst support provide structural and sentiment benefits, but these factors have less immediate influence than the cancer-vaccine readout. The stock had already posted an exceptionally strong rally, leaving the valuation highly sensitive to new clinical information. Nasdaq-100 inclusion article
• Negative Sentiment: Partial trial data appeared on social media ahead of Moderna and Merck’s planned ESMO presentation, triggering extreme volatility and a sharp selloff. The premature release disrupted the expected news event and encouraged a “sell-the-news” reaction. CNBC data leak article
• Negative Sentiment: Although clinically meaningful, the 42% reduction fell short of the market’s very high expectations after Moderna’s dramatic run-up. Investors also questioned whether the results will translate beyond melanoma, how quickly the product could reach the market, and its eventual commercial opportunity. The breach of near-term technical support and heightened trading swings add further pressure. Zacks analysis

Insider Activity

In other news, insider Shannon Klinger sold 3,471 shares of the company's stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 39,145 shares of Moderna stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the sale, the president owned 1,636,565 shares of the company's stock, valued at approximately $361,222,626.80. This trade represents a 2.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 197,251 shares of company stock worth $33,875,904 over the last ninety days. 10.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. William Blair initiated coverage on shares of Moderna in a research note on Friday, August 28th. They issued an "outperform" rating for the company. Royal Bank Of Canada reiterated a "sector perform" rating and issued a $130.00 target price on shares of Moderna in a report on Wednesday, August 19th. Brookline Capital Markets restated a "buy" rating on shares of Moderna in a research note on Wednesday, August 19th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Moderna in a report on Friday, August 28th. They issued a "hold" rating and a $125.00 target price on the stock. Finally, Bradesco Corretora upgraded shares of Moderna to an "outperform" rating in a research note on Friday, August 28th. Seven investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $103.95.

Moderna Stock Down 1.2%

Shares of MRNA opened at $200.10 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The company's 50 day simple moving average is $172.79 and its 200-day simple moving average is $96.96. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $254.48.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping analysts' consensus estimates of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million during the quarter, compared to analysts' expectations of $102.93 million. During the same quarter in the prior year, the business earned ($2.13) EPS. Moderna's quarterly revenue was up 2.1% compared to the same quarter last year. Sell-side analysts expect that Moderna, Inc. will post -6.11 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.